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In recent years, the treatment of moderate to severe psoriasis has beneﬁted from the development of targeted biologicals.
Assessing this new class of drugs calls for precise modalities of severity/improvement ratings of the disease. Bioengineering-
driven dermometrology aims at improving objective and quantitative assessments of disease severity and treatment eﬃcacy. Skin
capacitance mapping/imaging is one of those emerging methods. Among its clinical applications, psoriasis capacitance mapping
(PCM) was introduced in order to assess both skin scaliness and water trapping inside the stratum corneum (inﬂammatory
serum deposits) on lesional skin. PCM was used for assessing the therapeutic eﬀects of ustekinumab on target lesions of 5
psoriatic patients. The reduction in the inﬂammatory dampness of the stratum corneum was conveniently seen after a 1-month
ustekinumab treatment. The present pilot study suggests that PCM could be used as a fast and convenient method for assessing
the anti-inﬂammatory eﬃcacy of ustekinumab and other biotherapies.
1.Introduction
Skin involvement of psoriasis is far from being trivial as it is
responsible for signiﬁcant physical and psychological mor-
bidity. This speciﬁc chronic, immuno-inﬂammatory derma-
tosis is characterized by the combination of increased kerat-
inocyte proliferation and defective keratinocyte maturation
(parakeratosis), associated with angiogenesis and inﬂamma-
tory cell recruitment [1–3]. The clinicopathological presen-
tations vary according to the type of psoriasis and the body
locations [4]. Currently, there is overall agreement in the
scientiﬁccommunitytoconsiderpsoriasisasanautoimmune
disease initiated and mediated by plasmacytoid cells and T
cells [2, 3, 5, 6].
Thepsoriasisareaandseverityindex(PASI)isconsidered
as an appropriate means for evaluating the global severity
of plaque-type psoriasis [7, 8]. However, in some instances,
PASI merely represents a gross evaluation, calling for more
precise information regarding the changes in early evolving
lesions [9]. Indeed, the interobserver reliability of visual
clinical gradings of the global condition is relatively poor
[9–12]. As a result, large variations between estimates of dif-
ferent clinicians impede scoring reproducibility. In addition,
the development of active tiny papular lesions of psoriasis
is notoriously blurred by the relative extent of the larger
plaques [9]. Some objective and quantitative approaches
possibly improve the precision and reproducibility of the
PASI scoring [11–13]. New assessment methods were further
welcomedbecauserecentandupcomingpsoriasistreatments
oﬀer new opportunities [6, 7, 9, 14], but also fuel some
uncertainties regarding the objectivity and speciﬁcity of the
assessment of psoriasis evolution.
Psoriatic lesions are far less uniform in their histopatho-
logical structure than the uninvolved surrounding skin [1].
The density of the inﬂammatory cell inﬁltrate, the vascular
hyperplasia, the epidermal thickening, and the extent in
hyperkeratosis and parakeratosis indeed show large inter-
and intraindividual variations [1, 4, 7]. The regular clinical
examination possibly detects some of the variations, but
dermoscopy and a few other speciﬁc noninvasive bioengi-
neering methods help identifying the clinical heterogeneity
with increased speciﬁcity and sensitivity [15, 16]. The same2 Journal of Biomedicine and Biotechnology
methods possibly help assessing the beneﬁts and adverse
eﬀects of antipsoriatic therapies, in particular the recent
pharmacological advances in biological therapies.
2. Pathobiology andFunctionalChanges
Psoriasis is fostered by the local activation of Th1 and Th17
cells in cooperation with CD123+ plasmacytoid dendritic
cells releasing a series of various proinﬂammatory cytokines
[3, 17, 18].
Among the various cytokines identiﬁed in excess in
psoriatic lesions [19], TNF-α p l a y sac e n tra lr o l e[ 9]. In addi-
tion, the heterodimeric IL-12 and IL-23 cytokines induce
na¨ ıve CD4+ lymphocytes to diﬀerentiate into Th1 cells and
Th17 cells. IL-23 is involved in the regulation of innate
defense eﬀector molecules, such as IL-17 and IL-22 present
in psoriasis. TNF-α is produced by a wide range of immune
and nonimmune cells. It exerts broad inﬂammatory eﬀects,
upregulating both the innate and adaptive immunity. It
activates a range of cells, including keratinocytes and dermal
dendrocytes.BothIL-12andIL-23areproducedprimarilyby
plasmacytoid dendritic cells. In turn, the cytokines activate
NK cells, CD4+ cells, CD8+ cells, and the diﬀerentiation
of CD4+ cells into Th1 and Th17 cells. TNF-α triggers the
production of IL-1, IL-6, IL-8, and NF-κB contributing to
the initiation of a cascade of inﬂammatory events leading to
oedema and recruitment of neutrophils.
3.Real-Time PsoriasisCapacitanceMapping
Any change in the structure of the stratum corneum (SC)
is potentially associated with alterations of both its barrier
function and water holding capacity [20–22]. These changes
aﬀect the electrical properties of the skin [23]. In the
past decade, a method of nonoptical imaging based on
skin capacitance mapping/imaging was developed, showing
detailed diﬀerences in hydration of the SC over the skin
surface [24]. Skin capacitance mapping relies on silicon
image sensor technology, initially developed for sensing
ﬁngerprints in biometric security procedures [24–27]. Con-
trasting with skin capacitance mapping, all other available
skin electrometric methods only provide average data on SC
electrical properties over the area of the measuring probes.
With the latter methods, it is impossible to disclose any
heterogeneity in skin surface hydration over the test area.
In addition, it is impossible to appreciate the relative impact
of the partial close apposition of the probe onto rough skin
surfaces. This situation obviously interferes with the overage
assessment of the global SC hydration.
Psoriasis is conveniently explored using psoriasis capac-
itance mapping (PCM) which is the application of skin
capacitance mapping/imaging to the speciﬁc dermatosis
[28]. PCM is obtained using the SkinChip device (ST
microelectronics, Geneva, Switzerland and L’Or´ eal, Paris,
France). The device is designed for computer recordings
of the skin surface hydration and microrelief. The sensor
contains92160microcapacitorsdispersedona18∗12.8mm
plate protected by a thin silicon oxide layer. It allows
simultaneous skin capacitance measurements every 50μm.
The probe must be closely applied to the skin surface for
about 5 seconds at the most in order to collect relevant
information without interference with the water ﬂux and
sweat collection inside the SC.
In practice, the real-time skin capacitance nonoptical
images are acquired and displayed on a computer screen
where capacitance values present as pixels within a range of
256 gray levels. When a close contact is secured between the
probe and the skin surface, the darker pixels correspond to
high capacitance spots, and the clear pixels reveal spots with
lower capacitance values [24, 26, 29, 30]. The PCM-derived
mean gray level is representative of the average skin surface
hydration.
Psoriasis is the paradigm of inﬂammatory hyperkeratotic
dermatoses. PCM reveals a patchwork of diﬀerent electrical
properties on lesional skin [28]. Whitish low capacitance
is typical for stable hyperkeratotic plaques. More acute
inﬂammation and evolving plaques show a darker density
of high-capacitance spots [28]. This aspect is likely related
to sites exhibiting increased transepidermal water loss [31].
PCM can thus provide clues of disease activity in any stage of
psoriasis and can be used to monitor therapy over time on a
target lesion.
4.Ustekinumab andPCM
At present, biologicals approved for psoriasis encompass a
few TNF antagonists (adalimumab, efalizumab, etanercept)
and ustekinumab, an anti-p40 antibody altering the het-
erodimeric IL-12 and IL-23 cytokine functions. The present
observations were focused on 5 patients aged 48 ± 6y e a r s
suﬀering from long-standing plaque type psoriasis admixed
with smaller papules dispersed on the trunk and limbs. The
patients had been enrolled in an ustekinumab trial. In addi-
tion to the regular protocol, the present noninvasive PCM
observations were conducted with the understanding and
consent of the volunteers. In each of them, PCM assessments
were performed on ﬁve psoriatic papular lesions located on
the trunk and each of the limbs. The observations were
performed at entry in the ustekinumab treatment trial and
one month after a single 45mg ustekinumab subcutaneous
injection. No other systemic or topical treatment was used in
the meantime.
At entry in the study, the psoriatic lesions corresponded
toenlargingpapulesunresponsivetoprevioussystemictreat-
ments. At the PCM examination, they showed a patchwork
of darker and lighter spots Figures 1(a) and 1(b).I ne a c h
volunteer, the relative area (%) of the darker spots was
averaged for the 5 ﬁelds. Results were expressed as means
and standard deviations (SD) for the relative area. The mean
a r e a sw e r ec o m p a r e db yt h eS t u d e n t ’ st-test. Results were
consideredtobesigniﬁcantatthe5%criticallevel(P<0.05).
A l lc a l c u l a t i o n sw e r ep e r f o r m e du s i n gS A S( v e r s i o n8 . 2f o r
Windows) and S-PLUS (version 6.1) statistical packages.
Both the patterns and the relative areas of darker spots
showed large interlesional variations. When pooling all data
(5 sites) in the 5 patients before and after a 1-month ustek-
inumabtherapy,aglobalsigniﬁcantdiﬀerence(P<0.01)was
yielded in the mean relative areas of darker spots which wereJournal of Biomedicine and Biotechnology 3
(a) Pretreatment aspect. (b) After a 1-month ustekinumab treatment.
Figure 1: Skin capacitance mapping of a psoriatic lesion, showing a patchwork of white hyperkeratotic areas and a darker inﬂammatory area
(surface area: 18 ∗12.8 mm).
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Figure 2: Relative area (means ± SD) of the PCM darker pixels in
5 psoriatic lesions from 5 patients (A to E) at inclusion and after
a 1-month ustekinumab treatment. The global reduction in high
capacitance inﬂammatory areas is signiﬁcant (P<0.01).
abated during the ﬁrst month of ustekinumab treatment
(Figure 2).
5. Conclusion
Psoriasis treatment has come a long way for the past decade.
In earlier days, the trial-and-error approach to medical
innovation represented the roots of psoriasis management.
A new era recently emerged when researchers made progress
in improving the understanding of the pathobiological
processesinvolvedinpsoriasis[3,32].Toolsbecameavailable
to investigators and clinicians for scrutinizing the biological
background supporting the therapeutic eﬃcacy. Research in
genetics and immunopathology has improved the under-
standing of the modalities by which therapies actually work.
It has proved especially rewarding in providing a means
for developing appropriate drugs following rational designs
[33].
Psoriasis is a chronic, recurrent, immunoinﬂammatory
skindisorderassociatedwithsystemiccomorbidities[9].The
disease varies in severity and exhibits various morphological
subtypes, ranging from a few scaly papules to generalized
erythematous plaques and pustules. Depending on the sever-
ity of the disease, psoriasis is potentially responsible for
major negative physical, economical and psychosocial eﬀects
on patients. Recently, speciﬁc biologicals were developed to
targetsomestepsofthepsoriaticbiopathology.Ustekinumab
is one of the promising drugs in this ﬁeld [34].
The present pilot study suggests that PCM is sensitive
enough to disclose a decrease in inﬂammation in evolving
psoriaticpapuleswhileonearlyustekinumabtreatment.This
sign likely represents the inﬂammatory step initiating psoria-
sisprogression.PCMcouldbeusedtotheearlyidentiﬁcation
of responders to biologicals. Indeed, the improvement of
psoriasis as revealed by PCM was disclosed in this study
after a one-month treatment that is much shorter than the
12-week period usually respected for assessing changes in
the PASI score. Of note, the mean time to peak serum
ustekinumab concentration is about 12 days.
Plaque psoriasis is the most common form, aﬀecting ap-
proximately 85–90% of individuals with the condition. The
disease manifests as raised, well-demarcated, erythematous,
and frequently pruritic/painful plaques with silvery scales
[2].Approximately25%ofindividualswithpsoriasisdevelop
moderate-to-severe disease with widely disseminated lesions
[2]. During psoriasis progression, it is not infrequent to see
new early papular lesions that are much more active than4 Journal of Biomedicine and Biotechnology
the larger stable plaques [1]. The present study focused on
suchguttatepapularlesionsbecauseitwasexpectedthatthey
could represent more sensitive models for evolving psoriasis.
Psoriasis is associated with multiple comorbidities, in-
cluding psoriatic arthritis, depression, cardiovascular dis-
ease, hypertension, obesity, diabetes, metabolic syndrome,
and Crohn’s disease [9, 35, 36]. It is unknown if breaking the
inﬂammatory evolution of papular psoriasis represents a
markerfortheevolutionofpsoriaticcomorbidities.Therela-
tionship, if any, between PCM data and the evolution of each
of the psoriatic comorbidities remains to be settled.
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